Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Nanosonics Limited ( (AU:NAN) ) has provided an announcement.
Nanosonics Limited reported a strong financial performance for FY25, with a 17% increase in total revenue to $198.6 million and a 72% rise in profit before tax. The company achieved significant milestones, including the launch of next-generation trophon technology and FDA clearance for its CORIS system, which is expected to enhance its market leadership and expand its portfolio. The company’s strategic investments in R&D and operational advancements, such as a new US manufacturing facility, are set to support future growth and shareholder value.
The most recent analyst rating on (AU:NAN) stock is a Buy with a A$5.15 price target. To see the full list of analyst forecasts on Nanosonics Limited stock, see the AU:NAN Stock Forecast page.
More about Nanosonics Limited
Nanosonics Limited is a leader in infection prevention solutions, primarily focusing on ultrasound probe reprocessing technologies. The company is known for its trophon devices and is expanding its market presence with innovations in endoscope cleaning systems.
Average Trading Volume: 725,502
Technical Sentiment Signal: Buy
Current Market Cap: A$1.23B
For detailed information about NAN stock, go to TipRanks’ Stock Analysis page.